Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 12/20 | 0.44 |
| ▸ | THRA | P10827 | 9/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6864242 | 0.87 | THRB (0.49) | THRBTHRAOPRK1RORCLPAR1 | |
| SCHEMBL6863331 | 0.81 | THRB (0.66) | THRBTHRAALDH1A1GAA | |
| SCHEMBL6862542 | 0.81 | MTNR1A (0.43) | PPARGOPRK1MTNR1AMTNR1BCYP17A1 | |
| SCHEMBL6865527 | 0.79 | ALDH1A1 (0.39) | ALDH1A1GAALPAR1 | |
| SCHEMBL282445 | 0.76 | THRB (0.49) | THRBTHRAOPRK1RORC | |
| SCHEMBL7114452 | 0.75 | THRB (0.50) | THRBTHRAGAARORC | |
| SCHEMBL26714182 | 0.74 | THRB (0.47) | THRBTHRAOPRK1RORCLPAR1 | |
| SCHEMBL666032 | 0.74 | THRB (0.43) | THRBTHRAOPRK1ALDH1A1GAA | |
| SCHEMBL6864460 | 0.74 | THRB (0.48) | THRBTHRAOPRK1ALDH1A1GAA | |
| SCHEMBL667473 | 0.74 | THRB (0.45) | THRBTHRAOPRK1ALDH1A1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6803480-B2 | THERAPEUTIC TREATMENT AND/OR PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 2004-10-12 | — | — | US | disclosed |
| US-20030203898-A1 | Therapeutic treatment and/or prophylaxis of arteriosclerosis and hypercholesterolaemia | BAYER AKTIENGESELLSCHAFT (DE) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203898-A1 | Therapeutic treatment and/or prophylaxis of arteriosclerosis and hypercholesterolaemia | APOB, HMGCR, PCSK9 | THRB 2653/4885THRA 2817/4885PPARG 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.